These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

696 related articles for article (PubMed ID: 9649144)

  • 21. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
    Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
    Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.
    Dingemans AM; Witlox MA; Stallaert RA; van der Valk P; Postmus PE; Giaccone G
    Clin Cancer Res; 1999 Aug; 5(8):2048-58. PubMed ID: 10473085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients.
    Parissenti AM; Chapman JA; Kahn HJ; Guo B; Han L; O'Brien P; Clemons MP; Jong R; Dent R; Fitzgerald B; Pritchard KI; Shepherd LE; Trudeau ME
    Breast Cancer Res Treat; 2010 Jan; 119(2):347-56. PubMed ID: 19771508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topoisomerase IIalpha expression in ductal carcinoma in situ of the breast: a preliminary study.
    Shpitz B; Bomstein Y; Zehavi T; Bernheim J; Liverant S; Kaufman Z; Buklan G; Klein E
    Hum Pathol; 2000 Oct; 31(10):1249-54. PubMed ID: 11070118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
    Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
    Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas.
    Taniguchi K; Wakabayashi T; Yoshida T; Mizuno M; Yoshikawa K; Kikuchi A; Nakashima N; Yoshida J
    J Neurosurg; 1999 Sep; 91(3):477-82. PubMed ID: 10470824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.
    Rudolph P; MacGrogan G; Bonichon F; Frahm SO; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM; Parwaresch R
    Breast Cancer Res Treat; 1999 May; 55(1):61-71. PubMed ID: 10472780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
    Schindlbeck C; Janni W; Shabani N; Kornmeier A; Rack B; Rjosk D; Gerber B; Braun S; Sommer H; Friese K
    J Cancer Res Clin Oncol; 2005 Aug; 131(8):539-46. PubMed ID: 15887027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.
    MacGrogan G; Mauriac L; Durand M; Bonichon F; Trojani M; de Mascarel I; Coindre JM
    Br J Cancer; 1996 Nov; 74(9):1458-65. PubMed ID: 8912545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
    Yu Y; Xiang H; He XM; Yang HJ; Zong XY
    Asian Pac J Cancer Prev; 2013; 14(4):2401-6. PubMed ID: 23725148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
    Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
    Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A
    Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topoisomerase IIalpha and other drug resistance markers in advanced non-small cell lung cancer.
    Dingemans AC; van Ark-Otte J; Span S; Scagliotti GV; van der Valk P; Postmus PE; Giaccone G
    Lung Cancer; 2001 May; 32(2):117-28. PubMed ID: 11325482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of topoisomerase IIalpha, Ki-67, proliferating cell nuclear antigen, p53, and argyrophilic nucleolar organizer regions in vulvar squamous lesions.
    Brustmann H; Naudé S
    Gynecol Oncol; 2002 Aug; 86(2):192-9. PubMed ID: 12144828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.
    von Minckwitz G; Sinn HP; Raab G; Loibl S; Blohmer JU; Eidtmann H; Hilfrich J; Merkle E; Jackisch C; Costa SD; Caputo A; Kaufmann M;
    Breast Cancer Res; 2008; 10(2):R30. PubMed ID: 18380893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.
    Penault-Llorca F; Cayre A; Bouchet Mishellany F; Amat S; Feillel V; Le Bouedec G; Ferrière JP; De Latour M; Chollet P
    Int J Oncol; 2003 Jun; 22(6):1319-25. PubMed ID: 12739000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.
    Levesque MA; Clark GM; Yu H; Diamandis EP
    Br J Cancer; 1995 Sep; 72(3):720-7. PubMed ID: 7545416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.